^
    4d
    Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC. (PubMed, J Thorac Oncol)
    Olomorasib + pembrolizumab demonstrated manageable safety and promising antitumor activity in patients with KRAS G12C-mutant advanced NSCLC across PD-L1 expression levels, especially in the high PD-L1 first-line setting.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • olomorasib (LY3537982)
    16d
    A Study of Olomorasib (LY3537982) in Healthy Japanese Participants (clinicaltrials.gov)
    P1, N=188, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olomorasib (LY3537982)
    22d
    KaRAnaSa: A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Janssen Research & Development, LLC
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Rybrevant (amivantamab-vmjw) • olomorasib (LY3537982)
    1m
    A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02 (ChiCTR2500111173)
    P3, N=700, Not yet recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
    New P3 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Imfinzi (durvalumab) • olomorasib (LY3537982)
    2ms
    A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function (clinicaltrials.gov)
    P1, N=32, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olomorasib (LY3537982)
    2ms
    A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants (clinicaltrials.gov)
    P1, N=120, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olomorasib (LY3537982)
    2ms
    A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants (clinicaltrials.gov)
    P1, N=46, Completed, Eli Lilly and Company | Recruiting --> Completed
    Trial completion
    |
    olomorasib (LY3537982)
    3ms
    A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Eli Lilly and Company
    New P1 trial
    |
    olomorasib (LY3537982)
    4ms
    A Study of Olomorasib (LY3537982) in Healthy Japanese Participants (clinicaltrials.gov)
    P1, N=188, Not yet recruiting, Eli Lilly and Company
    New P1 trial
    |
    olomorasib (LY3537982)
    5ms
    The complex journey of targeting RAS in oncology. (PubMed, BMC Cancer)
    This breakthrough has led to the development of targeted therapeutics, such as sotorasib and adagrasib, for KRAS G12C-mutated non-small cell lung cancer (NSCLC)...New inhibitors, such as LY3537982 or GDC-6036, are promising, but achieving effective and selective RAS inhibition remains a significant challenge...Challenges such as off-target effects and delivery issues remain significant barriers in the introduction of effective therapies based on RAS inhibitors. This overview highlights the evolving nature of targeting RAS in cancer therapy.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • KRAS mutation • KRAS G12C • RAS mutation • KRAS G12
    |
    Lumakras (sotorasib) • Krazati (adagrasib) • divarasib (RG6330) • olomorasib (LY3537982)
    5ms
    A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, Eli Lilly and Company
    New P1 trial
    |
    olomorasib (LY3537982)
    7ms
    KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials. (PubMed, Crit Rev Oncol Hematol)
    This analysis suggests that KRAS-G12C inhibitors in combination with anti-EGFR agents may provide a doubled ORR and 1.5-month PFS benefit compared to monotherapy in previously treated mCRC patients, but with a doubled grade 3-4 TRAEs, including skin toxicities, paronychia, and hypomagnesemia. Treatment preferences should be individualized in these highly pretreated patients.
    P1/2 data • Retrospective data • Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Lumakras (sotorasib) • Krazati (adagrasib) • divarasib (RG6330) • olomorasib (LY3537982)